MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1
Oncogene (2016) - Comments
pubmed: 27157613  doi: 10.1038/onc.2016.151  issn: 0950-9232  issn: 1476-5594 

L Venturutti, R I Cordo Russo, M A Rivas, M F Mercogliano, F Izzo, R H Oakley, M G Pereyra, M De Martino, C J Proietti, P Yankilevich, J C Roa, P Guzmán, E Cortese, D H Allemand, T H Huang, E H Charreau, J A Cidlowski, R Schillaci, P V Elizalde